Caninsulin VetPen is a veterinary-formulated porcine insulin zinc suspension offered in a pen format that simplifies dosing for dogs and reduces wastage compared with vial-only products. It is positioned as a cost-conscious, clinic-friendly option with dosing pens that improve owner compliance versus vial-based insulins like Prozinc, while providing a more veterinary-focused formulation than human products such as Lantus or Humulin N.
Prefilled pen
Vet-formulated
Prefilled pen
Vet-formulated
Review Summary
"Owners frequently praise Caninsulin VetPen for easy dosing and generally reliable glycemic control in dogs, though some report occasional supply issues or variability between batches. The pen format and veterinary focus are cited as major advantages for long‑term use."
Tail-approved ease
Porcine zinc insulin formulated specifically for dogs and licensed for veterinary use.
Tail-approved ease
Porcine zinc insulin formulated specifically for dogs and licensed for veterinary use.
Increased Safety & Security
Time-Saving Convenience
Skill Development & Mastery
Caninsulin VetPen is a veterinary-formulated porcine insulin zinc suspension offered in a pen format that simplifies dosing for dogs and reduces wastage compared with vial-only products. It is positioned as a cost-conscious, clinic-friendly option with dosing pens that improve owner compliance versus vial-based insulins like Prozinc, while providing a more veterinary-focused formulation than human products such as Lantus or Humulin N.
Prefilled pen
Vet-formulated
Tail-approved ease
Porcine zinc insulin formulated specifically for dogs and licensed for veterinary use.
Available as a prefilled VetPen option for more precise dosing and easier owner administration.
Prefilled pen
Vet-formulated
Tail-approved ease
Porcine zinc insulin formulated specifically for dogs and licensed for veterinary use.
Available as a prefilled VetPen option for more precise dosing and easier owner administration.
$150-260 CAD
Trilostane (Vetoryl)
Vetoryl (trilostane) is a licensed oral veterinary product indicated primarily for hyperadrenocorticism (Cushing’s disease) in dogs and is included here as a metabolic regulator with a strong regulatory and safety profile; its clinical value lies in addressing endocrine causes of insulin resistance and complex metabolic dysfunction. Compared with the antidiabetic agents on this list, Vetoryl targets a different but often related disease process and offers the technical advantage of being a fully authorized, label-supported product with established monitoring protocols, which can improve outcomes in dogs whose diabetes is complicated by adrenal disease. Economically, Vetoryl commands a premium relative to many compounded oral options due to its branded status and associated veterinary monitoring requirements, but that cost is offset by regulatory support and predictable supply.
Controls cortisol excess - cape optional
Once-daily dosing
Controls cortisol excess - cape optional
Once-daily dosing
Review Summary
"Vetoryl (trilostane) is widely regarded as effective for managing canine Cushing's disease, with many owners reporting clear clinical improvement though frequent monitoring and dose adjustments are commonly needed."
Licensed canine formulation
Trilostane (Vetoryl) is a licensed oral medication for treating hyperadrenocorticism by inhibiting corticosteroid synthesis.
Licensed canine formulation
Trilostane (Vetoryl) is a licensed oral medication for treating hyperadrenocorticism by inhibiting corticosteroid synthesis.
Increased Safety & Security
Time-Saving Convenience
Vetoryl (trilostane) is a licensed oral veterinary product indicated primarily for hyperadrenocorticism (Cushing’s disease) in dogs and is included here as a metabolic regulator with a strong regulatory and safety profile; its clinical value lies in addressing endocrine causes of insulin resistance and complex metabolic dysfunction. Compared with the antidiabetic agents on this list, Vetoryl targets a different but often related disease process and offers the technical advantage of being a fully authorized, label-supported product with established monitoring protocols, which can improve outcomes in dogs whose diabetes is complicated by adrenal disease. Economically, Vetoryl commands a premium relative to many compounded oral options due to its branded status and associated veterinary monitoring requirements, but that cost is offset by regulatory support and predictable supply.
Controls cortisol excess - cape optional
Once-daily dosing
Licensed canine formulation
Trilostane (Vetoryl) is a licensed oral medication for treating hyperadrenocorticism by inhibiting corticosteroid synthesis.
Requires careful dose titration and frequent monitoring of cortisol and electrolytes due to risk of hypoadrenocorticism.
Controls cortisol excess - cape optional
Once-daily dosing
Licensed canine formulation
Trilostane (Vetoryl) is a licensed oral medication for treating hyperadrenocorticism by inhibiting corticosteroid synthesis.
Requires careful dose titration and frequent monitoring of cortisol and electrolytes due to risk of hypoadrenocorticism.
$200-500 CAD
Thyrosyn
Thyrosyn occupies a niche in the veterinary thyroid replacement market by offering formulations and tablet sizes intended for small-breed or sensitive canine patients where fine-tuned dosing is required. It is often chosen when clinicians need more tailored dosing than standard tablets provide; however, that specificity can come with higher per-dose costs compared with mass-market options such as Soloxine or generic levothyroxine tablets.
Flexible dosing
Economy option
Flexible dosing
Economy option
Review Summary
"Thyrosyn receives mixed-to-positive feedback: many owners see good symptom control and improved quality of life, while others experience variable response or require frequent blood testing and dose adjustments. Reviews indicate good efficacy for some dogs but less consistency across the board."
Reliable supply
Formulation provides liothyronine (T3) for more rapid onset in selected or refractory cases (used less commonly than T4).
Reliable supply
Formulation provides liothyronine (T3) for more rapid onset in selected or refractory cases (used less commonly than T4).
Increased Safety & Security
Time-Saving Convenience
Thyrosyn occupies a niche in the veterinary thyroid replacement market by offering formulations and tablet sizes intended for small-breed or sensitive canine patients where fine-tuned dosing is required. It is often chosen when clinicians need more tailored dosing than standard tablets provide; however, that specificity can come with higher per-dose costs compared with mass-market options such as Soloxine or generic levothyroxine tablets.
Flexible dosing
Economy option
Reliable supply
Formulation provides liothyronine (T3) for more rapid onset in selected or refractory cases (used less commonly than T4).
Typically reserved for short-term use or specialist-managed combination therapy alongside T4 under veterinary oversight.
Flexible dosing
Economy option
Reliable supply
Formulation provides liothyronine (T3) for more rapid onset in selected or refractory cases (used less commonly than T4).
Typically reserved for short-term use or specialist-managed combination therapy alongside T4 under veterinary oversight.
$60-200 CAD
Percorten-V Injectable
Percorten‑V (desoxycorticosterone pivalate, DOCP) Injectable is the market‑leading long‑acting parenteral mineralocorticoid for dogs with primary hypoadrenocorticism, delivering predictable monthly electrolyte control. Its technical advantage over oral Florinef is steadier mineralocorticoid replacement with fewer compliance issues and often better long‑term cost‑effectiveness despite higher upfront injection visit charges; because it lacks glucocorticoid activity it is routinely used alongside a separate glucocorticoid such as prednisolone.
Long-acting injection
Fewer daily pills
Long-acting injection
Fewer daily pills
Review Summary
"Percorten-V is widely praised for consistent, long-lasting mineralocorticoid replacement and predictable monthly control; main complaints are expense and the necessity of veterinary-administered injections."
Bounce-back energy
Monthly injectable desoxycorticosterone pivalate for reliable mineralocorticoid replacement.
Bounce-back energy
Monthly injectable desoxycorticosterone pivalate for reliable mineralocorticoid replacement.
Increased Safety & Security
Time-Saving Convenience
Percorten‑V (desoxycorticosterone pivalate, DOCP) Injectable is the market‑leading long‑acting parenteral mineralocorticoid for dogs with primary hypoadrenocorticism, delivering predictable monthly electrolyte control. Its technical advantage over oral Florinef is steadier mineralocorticoid replacement with fewer compliance issues and often better long‑term cost‑effectiveness despite higher upfront injection visit charges; because it lacks glucocorticoid activity it is routinely used alongside a separate glucocorticoid such as prednisolone.
Long-acting injection
Fewer daily pills
Bounce-back energy
Monthly injectable desoxycorticosterone pivalate for reliable mineralocorticoid replacement.
Provides consistent electrolyte control with less frequent dosing than oral options.
Long-acting injection
Fewer daily pills
Bounce-back energy
Monthly injectable desoxycorticosterone pivalate for reliable mineralocorticoid replacement.
Provides consistent electrolyte control with less frequent dosing than oral options.
$120-250 CAD
Percorten-V DOCP Injection
Percorten-V (DOCP) injection is the standard long-acting mineralocorticoid replacement for canine hypoadrenocorticism, delivering predictable monthly electrolyte control and removing the need for daily oral mineralocorticoid dosing. Its technical advantage is a dependable, clinic-administered depot effect that reduces owner pill burden and stabilizes sodium/potassium ratios, which—despite requiring periodic veterinary visits—often lowers long-term monitoring variability and overall management costs compared with daily oral alternatives.
Stabilizes electrolytes
Long-lasting injection
Stabilizes electrolytes
Long-lasting injection
Review Summary
"Percorten-V (DOCP) injections are widely praised for reliably managing Addison's disease with monthly dosing and predictable clinical improvement; owners appreciate the effectiveness though they mention cost and the need for periodic electrolyte monitoring."
Monthly lifesaver
DOCP (Percorten-V) is a long-acting injectable mineralocorticoid used to replace aldosterone in primary hypoadrenocorticism.
Monthly lifesaver
DOCP (Percorten-V) is a long-acting injectable mineralocorticoid used to replace aldosterone in primary hypoadrenocorticism.
Increased Safety & Security
Time-Saving Convenience
Percorten-V (DOCP) injection is the standard long-acting mineralocorticoid replacement for canine hypoadrenocorticism, delivering predictable monthly electrolyte control and removing the need for daily oral mineralocorticoid dosing. Its technical advantage is a dependable, clinic-administered depot effect that reduces owner pill burden and stabilizes sodium/potassium ratios, which—despite requiring periodic veterinary visits—often lowers long-term monitoring variability and overall management costs compared with daily oral alternatives.
Stabilizes electrolytes
Long-lasting injection
Monthly lifesaver
DOCP (Percorten-V) is a long-acting injectable mineralocorticoid used to replace aldosterone in primary hypoadrenocorticism.
Administered by deep IM or SC injection approximately every 25–30 days with concurrent glucocorticoid management as indicated.
Stabilizes electrolytes
Long-lasting injection
Monthly lifesaver
DOCP (Percorten-V) is a long-acting injectable mineralocorticoid used to replace aldosterone in primary hypoadrenocorticism.
Administered by deep IM or SC injection approximately every 25–30 days with concurrent glucocorticoid management as indicated.
$100-350 CAD